Effect of Single-Session, Cryogen-Cooled Monopolar Radiofrequency Therapy on Sexual Function in Women with Vaginal Laxity: The VIVEVE I Trial
Open Access
- 1 March 2018
- journal article
- research article
- Published by SAGE Publications in Journal of Women's Health
- Vol. 27 (3) , 297-304
Abstract
Objective: This subanalysis of the VIVEVE I trial aimed to evaluate the impact of cryogen-cooled monopolar radiofrequency (CMRF) therapy, for the treatment of vaginal laxity, on the domains of sexual function included in the Female Sexual Function Index (FSFI). Materials and Methods: The VIVEVE I clinical trial was prospective, randomized, single-blind, and Sham-controlled. Nine clinical study centers in Canada, Italy, Spain, and Japan were included. This subanalysis included premenopausal women with self-reported vaginal laxity who had ≥1 term vaginal delivery and a baseline FSFI total score ≤26.5, indicating sexual dysfunction. Enrolled subjects were randomized (2:1) to receive CMRF therapy [Active (90 J/cm 2 ) vs. Sham (≤1 J/cm 2 )] delivered to the vaginal tissue. Independent analyses were conducted for each FSFI domain to evaluate both the mean change, as well as the clinically important change for Active- versus Sham-treated subjects at 6 months post-intervention. Results: Subjects randomized to Active treatment ( n = 73) had greater improvement than Sham subjects ( n = 35) on all FSFI domains of sexual function at 6 months postintervention. The analysis of covariance change from baseline analyses showed statistically significant improvements, in favor of Active treatment, for sexual arousal ( p = 0.004), lubrication ( p = 0.04), and orgasm ( p = 0.007). In addition, Active treatment was associated with clinically important and statistically significant improvements in sexual desire [Odds ratio (OR) = 3.01 (1.11–8.17)], arousal [OR = 2.73 (1.06–7.04)], and orgasm [OR = 2.58 (1.08–6.18)]. Conclusions: This subanalysis showed CMRF therapy is associated with statistically significant and clinically important improvements in sexual function in women with vaginal laxity. These findings provide the first randomized, placebo-controlled energy-based device evidence for functional improvements associated with a nonsurgical modality for a highly prevalent and undertreated condition.Keywords
This publication has 41 references indexed in Scilit:
- Effect of Single-Treatment, Surface-Cooled Radiofrequency Therapy on Vaginal Laxity and Female Sexual Function: The VIVEVE I Randomized Controlled TrialThe Journal of Sexual Medicine, 2017
- Safety and Complications of More Than 1500 Small-Incision Lenticule Extraction ProceduresOphthalmology, 2014
- Nonsurgical transurethral collagen denaturation for stress urinary incontinence in women: 18‐month results from a prospective long‐term studyNeurourology and Urodynamics, 2010
- Radiofrequency Treatment of Vaginal Laxity after Vaginal Delivery: Nonsurgical Vaginal TighteningThe Journal of Sexual Medicine, 2010
- Does vaginal size impact sexual activity and function?International Urogynecology Journal, 2009
- Clinical Applications of Radiofrequency: Nonsurgical Skin Tightening (Thermage)Clinics in Plastic Surgery, 2009
- Sexual Problems and Distress in United States WomenObstetrics & Gynecology, 2008
- Nonablative cutaneous remodeling using radiofrequency devicesClinics in Dermatology, 2007
- Female genital tract morbidity and sexual function following vaginal delivery or lower segment caesarean sectionJournal of Obstetrics and Gynaecology, 2006
- The Female Sexual Function Index (FSFI): Cross-Validation and Development of Clinical Cutoff ScoresJournal of Sex & Marital Therapy, 2005